Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.11)
# 2,966
Out of 4,984 analysts
65
Total ratings
38.33%
Success rate
-1.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $575.06 | +41.20% | 8 | Aug 11, 2025 | |
| INCY Incyte | Maintains: Hold | $73 → $79 | $83.90 | -5.84% | 11 | Jul 30, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $7.64 | +43.98% | 1 | May 5, 2025 | |
| BIIB Biogen | Maintains: Buy | $210 → $199 | $143.68 | +38.50% | 4 | Apr 29, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $43 → $25 | $15.80 | +58.23% | 5 | Apr 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $60 → $76 | $58.59 | +29.71% | 2 | Mar 11, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $764.71 | +35.74% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $216.26 | +0.34% | 3 | Feb 3, 2025 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $23.90 | +33.89% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $14.06 | +255.62% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $45 | $32.34 | +39.15% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 → $53 | $48.78 | +8.65% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $2.02 | +2,573.27% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $9.13 | +64.29% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.44 | +326.54% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $49.76 | +40.68% | 4 | May 29, 2024 |
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $575.06
Upside: +41.20%
Incyte
Jul 30, 2025
Maintains: Hold
Price Target: $73 → $79
Current: $83.90
Upside: -5.84%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $7.64
Upside: +43.98%
Biogen
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $143.68
Upside: +38.50%
Keros Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $15.80
Upside: +58.23%
Protagonist Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $60 → $76
Current: $58.59
Upside: +29.71%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $764.71
Upside: +35.74%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $216.26
Upside: +0.34%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $23.90
Upside: +33.89%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $14.06
Upside: +255.62%
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $32.34
Upside: +39.15%
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $48.78
Upside: +8.65%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $2.02
Upside: +2,573.27%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $9.13
Upside: +64.29%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $8.44
Upside: +326.54%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $49.76
Upside: +40.68%